LKFT Stock Analysis: Lakefront Biotherapeutics | NASDAQ
Biotechnology | NASDAQ, USA | Market Cap: 1.997m USD | 12M Return: 9.5% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 4.71M
Qual. Beats: 0
Rev. Trend: 90.4%
Warnings
Tailwinds
Seasonality 10.5 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Lakefront Biotherapeutics NV (LKFT) is a Belgium-based biotechnology company developing therapies in oncology and immunology across the United States and Europe. Its pipeline includes GLPG3667 in Phase 2 trials for dermatomyositis and systemic lupus erythematosus, the point-of-care CD19 CAR-T candidate GLPG5101 in Phase 1/2 for relapsed/refractory non-Hodgkin lymphoma, and the BCMA CAR-T candidate GLPG5301 in Phase 1/2 for relapsed/refractory multiple myeloma. The company partners with Gilead Sciences and was renamed from Galapagos NV in May 2026.
Headquartered in Mechelen, Belgium, the company was incorporated in 1999 and listed on NASDAQ in 2015. As a clinical-stage biotech, the company depends largely on collaboration milestones and capital markets for funding rather than product revenue, a typical revenue profile for the sector while candidates remain in development.
- GLPG3667 phase 2 dermatomyositis and lupus readout timing
- Gilead collaboration milestones and royalties drive near-term revenue
- Point-of-care CAR-T manufacturing differentiates in competitive CD19 and BCMA markets
| Net Income: 488.8m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.09 > 0.02 and ΔFCF/TA 0.80 > 1.0 |
| NWC/Revenue: 283.6% < 20% (prev 1.10k%; Δ -817.5% < -1%) |
| CFO/TA -0.09 > 3% & CFO -301.6m > Net Income 488.8m |
| Net Debt (-2.98b) to EBITDA (652.3m): -4.56 < 3 |
| Current Ratio: 30.48 > 1.5 & < 3 |
| Outstanding Shares: last quarter (65.9m) vs 12m ago -0.04% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 28.23% > 50% (prev 6.85%; Δ 21.38% > 0%) |
| Interest Coverage Ratio: 269.0 > 6 (EBIT TTM 596.4m / Interest Expense TTM 2.22m) |
| A: 0.88 (Total Current Assets 3.06b - Total Current Liabilities 100.4m) / Total Assets 3.37b |
| B: 0.07 (Retained Earnings 228.3m / Total Assets 3.37b) |
| C: 0.16 (EBIT TTM 596.4m / Avg Total Assets 3.70b) |
| D: 27.33 (Book Value of Equity 3.25b / Total Liabilities 119.1m) |
| Altman-Z'' = 35.75 = AAA |
| DSRI: 0.28 (Receivables 54.0m/51.1m, Revenue 1.04b/275.6m) |
| GMI: 0.89 (GM 87.35% / 98.01%) |
| AQI: 0.64 (AQ_t 0.07 / AQ_t-1 0.11) |
| SGI: 3.79 (Revenue 1.04b / 275.6m) |
| TATA: 0.23 (NI 488.8m - CFO -301.6m) / TA 3.37b) |
| Beneish M = -1.91 (Cap -4..+1) = B |
As of July 08, 2026, the stock is trading at USD 30.58 with a total of 155,079 shares traded. Over the past week, the price has changed by +4.51%, over one month by +10.26%, over three months by +9.54% and over the past year by +9.54%.
Current recommended Stop Loss: 28.80 (which is 5.8% or 2.7 ATR below the current price).
Lakefront Biotherapeutics has no consensus analysts rating.
Market Cap EUR = 1.75b (2.00b USD * 0.8764 USD.EUR)
P/E Trailing = 3.605
P/E Forward = 344.8276
P/S = 1.9129
P/B = 0.5249
Revenue TTM = 1.04b EUR
EBIT TTM = 596.4m EUR
EBITDA TTM = 652.3m EUR
Long Term Debt = 4.85m EUR (estimated: total debt 6.43m - short term 1.58m)
Short Term Debt = 1.58m EUR (from shortTermDebt, last quarter)
Debt = 6.43m EUR (from shortLongTermDebtTotal, last quarter) (leases 6.43m already included)
Net Debt = -2.98b EUR (calculated: Debt 6.43m - CCE 2.98b)
Enterprise Value = 1.75b EUR (floored to Market Cap, CCE > MCap+Debt)
Interest Coverage Ratio = 269.0 (Ebit TTM 596.4m / Interest Expense TTM 2.22m)
EV/FCF = -5.64x (Enterprise Value 1.75b / FCF TTM -310.3m)
FCF Yield = -17.74% (FCF TTM -310.3m / Enterprise Value 1.75b)
FCF Margin = -29.73% (FCF TTM -310.3m / Revenue TTM 1.04b)
Net Margin = 46.83% (Net Income TTM 488.8m / Revenue TTM 1.04b)
Gross Margin = unknown ((Revenue TTM 1.04b - Cost of Revenue TTM 20.8m) / Revenue TTM)
Tobins Q-Ratio = 0.52 (Enterprise Value 1.75b / Total Assets 3.37b)
Interest Expense / Debt = 34.45% (Interest Expense 2.22m / Debt 6.43m)
Taxrate = 0.50% (70.0k / 14.0m)
NOPAT = 593.4m (EBIT 596.4m * (1 - 0.50%))
Current Ratio = 30.48 (Total Current Assets 3.06b / Total Current Liabilities 100.4m)
Debt / Equity = 0.00 (Debt 6.43m / totalStockholderEquity, last quarter 3.25b)
Debt / EBITDA = -4.56 (Net Debt -2.98b / EBITDA 652.3m)
Debt / FCF = 9.59 (negative FCF - burning cash) (Net Debt -2.98b / FCF TTM -310.3m)
Total Stockholder Equity = 2.90b (last 4 quarters mean from totalStockholderEquity)
RoA = 13.22% (Net Income 488.8m / Total Assets 3.37b)
RoE = 16.88% (Net Income TTM 488.8m / Total Stockholder Equity 2.90b)
RoCE = 20.57% (EBIT 596.4m / Capital Employed (Equity 2.90b + L.T.Debt 4.85m))
RoIC = 18.42% (NOPAT 593.4m / Invested Capital 3.22b)
WACC = 7.03% (E(1.75b)/V(1.76b) * Re(6.93%) + D(6.43m)/V(1.76b) * Rd(34.45%) * (1-Tc(0.01)))
Discount Rate = 6.93% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 9.33 | Cagr: 0.0%
[DCF] Fair Price = unknown (Cash Flow -310.3m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.25 | # QB: 0
Revenue Correlation: 90.42 | Revenue CAGR: 115.4% | SUE: N/A | # QB: 0
EPS current Quarter (2026-06-30): EPS=-0.97 | Chg30d=+84.46% | Revisions=-40% | Analysts=1
EPS next Quarter (2026-09-30): EPS=-0.83 | Chg30d=-9.15% | Revisions=-40% | Analysts=2
EPS current Year (2026-12-31): EPS=-2.29 | Chg30d=+63.12% | Revisions=-40% | GrowthEPS=-122.5% | GrowthRev=-86.5%
EPS next Year (2027-12-31): EPS=-2.58 | Chg30d=+0.00% | Revisions=-40% | GrowthEPS=-12.6% | GrowthRev=-12.2%
[Analyst] Revisions Ratio: -73% (up=0, down=8)